ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of “Buy” from Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXOGet Free Report) have been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $20.07.

ALXO has been the topic of several research reports. Jefferies Financial Group upgraded shares of ALX Oncology from a “hold” rating to a “buy” rating and upped their price objective for the company from $8.00 to $18.00 in a report on Friday, December 8th. Stifel Nicolaus decreased their price objective on shares of ALX Oncology from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, November 14th.

Read Our Latest Research Report on ALXO

Insider Activity at ALX Oncology

In other ALX Oncology news, CAO Shelly Pinto sold 2,717 shares of ALX Oncology stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $13.60, for a total value of $36,951.20. Following the completion of the transaction, the chief accounting officer now directly owns 78,591 shares of the company’s stock, valued at approximately $1,068,837.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 50.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of ALX Oncology in the third quarter valued at about $48,000. Forefront Analytics LLC acquired a new stake in shares of ALX Oncology during the third quarter worth about $66,000. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in ALX Oncology in the third quarter valued at approximately $96,000. Trexquant Investment LP raised its holdings in ALX Oncology by 16.6% in the second quarter. Trexquant Investment LP now owns 50,431 shares of the company’s stock valued at $379,000 after acquiring an additional 7,162 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its position in shares of ALX Oncology by 2.2% during the second quarter. Los Angeles Capital Management LLC now owns 146,677 shares of the company’s stock worth $1,102,000 after acquiring an additional 3,170 shares during the last quarter. Hedge funds and other institutional investors own 83.37% of the company’s stock.

ALX Oncology Trading Up 3.8 %

ALX Oncology stock opened at $16.45 on Tuesday. ALX Oncology has a 52 week low of $3.94 and a 52 week high of $17.42. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.66 and a current ratio of 5.66. The stock has a market capitalization of $819.54 million, a P/E ratio of -4.61 and a beta of 1.65. The stock has a 50-day simple moving average of $14.65 and a 200 day simple moving average of $9.83.

ALX Oncology Company Profile

(Get Free Report

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer.

Featured Stories

Analyst Recommendations for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.